An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate and a hemostatic agent. The substrate includes a first piece and a second piece that is joined with the first piece. The first piece includes the hemostatic agent and the second piece includes an active pharmaceutical ingredient. Kits, systems and methods are disclosed.

A lead for cardiac conduction system includes a proximal end, a lead body extending from the proximal end, and a distal end extending from the lead body. The lead body includes a non-conductive spacer. The distal end includes a helix electrode distal to the spacer. The lead further includes a ring electrode proximal to the spacer and surrounding a portion of the lead body. The helix electrode includes a core disposed within a helical space of the helix electrode. Another lead for cardiac conduction system includes a proximal end, a lead body extending from the proximal end, and a distal end extending from the lead body. The distal end includes a first helix electrode extending from the lead body and a second helix electrode extending from the lead body. A tip of the first helix electrode is distal to a tip of the second helix electrode.

The disclosure features surface coatings formed from dimeric steroid prodrugs for the extended delivery of a drug from a surface, and for the treatment of a disease or condition. Also provided herein are drug depots formed from dimeric steroid prodrugs for the extended delivery of a drug for use in combination with implantable medical devices. Said dimeric steroid prodrugs are represented by the formula D1-L-D2, wherein D1 and D2 are independently a steroid radical and L is a linker covalently linking D1 to D2.

A leadless biostimulator, and an electrical feedthrough assembly for use therewith, are described herein. The leadless biostimulator comprises an electrode body including a cup having an electrode wall extending distally from an electrode base around an electrode cavity, an electrode tip mounted on a distal end of the electrode body, and a filler in the electrode cavity between the electrode base and the electrode tip, wherein the filler includes a therapeutic agent. The electrode tip is configured to be placed in contact with target tissue to which a pacing impulse is to be transmitted by the leadless biostimulator. A pin extends proximally from the electrode base, wherein the pin is configured to be into contact with an electrical connector of an electronics assembly within a housing of the leadless biostimulator, and wherein the electrical feedthrough assembly is configured to be mounted on the housing of the leadless biostimulator.

An implantable medical lead having an elongated lead body extending from a proximal end to a distal end, at least one conductor extending within the lead body from the proximal end to the distal end, and a fixation member having a proximal end and a distal end, the proximal end of the electrode configured to be electrically coupled to the distal end of the lead body. The fixation member includes a first delivery port and a second delivery port for releasing a therapeutic agent from the fixation member to tissue of a patient, wherein the first delivery port is positioned along the proximal end of the fixation member to deliver the therapeutic agent to endothelial cells along an endothelial layer of tissue, and the second delivery port is positioned along the distal end of the fixation member and spaced a distance from the first delivery port to deliver the therapeutic agent to myocardial tissue within a myocardial layer of the tissue, and wherein no delivery ports are positioned within the distance that the second delivery port is spaced from the first delivery port.

Delivery of implantable active agent delivery components includes implanting a distal lead end of a lead into tissue at an implantation site. A delivery stylet is then inserted through a lead lumen of the lead. The delivery stylet includes a stylet body having a distal stylet end and an active agent delivery component detachably coupled to the distal stylet end. The active agent delivery component is inserted into the tissue at the implantation site by extending the distal stylet end of the delivery stylet from a distal lead end of the lead such that the active agent delivery component is inserted into the tissue at the implantation site. The active agent delivery component is then detached within the tissue at the implantation site and the delivery stylet may be retracted and removed from the lead lumen.

A distal electrode of an electrode assembly, for example, employed by an implantable medical electrical lead device, extends distally from a distal terminal end of a sleeve of the assembly; and the sleeve, which defines a longitudinal axis of the assembly, includes a plurality of channels that provide fluid communication between a steroid eluting component, which is seated in an external groove of the sleeve, and an area distal to the distal terminal end of the sleeve. Floors of some or all of the sleeve channels may angle toward the longitudinal axis of the assembly, being closer to the axis at the distal terminal end of the sleeve. The assembly may further include a proximal electrode secured to a proximal end of the sleeve, wherein the proximal electrode may be mounted around an outer surface of the sleeve or coupled to the sleeve by means of a coupling component.

A monolithic controlled release device (MCRD) for use with an implantable medical device includes a distal face, a proximal face opposite the distal face, and an outer circumferential surface extending between the distal face and the proximal face. A spline-shaped inner lumen extends between the distal face and the proximal face and radially inward from the outer circumferential surface. The MCRD is formed from a mixture including an active pharmaceutical ingredient.

Disclosed herein is an implantable medical device for implantation against cardiac tissue in the administration of electrotherapy to the cardiac tissue. The device includes a distal end and a monolithic controlled release device. The distal end includes a housing structure and a cavity within the housing structure. The cavity opens exterior the implantable medical device via a distal opening. The monolithic controlled release device is within the cavity and proximal the distal opening. The monolithic controlled release device includes a distal face, a proximal face opposite the distal face, an outer circumferential surface extending between the distal face and the proximal face, and a spline-shaped inner lumen extending between the distal face and the proximal face and radially inward from the outer circumferential surface. The monolithic controlled release device further includes an active pharmaceutical ingredient.

An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate and a hemostatic agent. The substrate includes a first piece and a second piece that is joined with the first piece. The first piece includes the hemostatic agent and the second piece includes an active pharmaceutical ingredient. Kits, systems and methods are disclosed.